Inhibition of selenocysteine tRNA[Ser]Sec aminoacylation provides evidence that aminoacylation is required for regulatory methylation of this tRNA
Lean tirzepatide when: Maximum weight loss is the goal (target greater than 20%) You have T2D with significant insulin resistance (SURPASS-2: 11.2 kg tirzepatide vs 5.7 kg semaglutide) You have moderate-to-severe obstructive sleep apnea with obesity (Zepbound is the only FDA-approved pharmacotherapy) You plateaued on semaglutide after 12+ months You have MASH and need the drug with the strongest resolution data (SYNERGY-NASH: 44 to 62% resolution) Your insurance covers Zepbound or Mounjaro You tolerated the 2.5 mg starting dose well during a prior trial Lean semaglutide when: You have established cardiovascular disease or high CV risk
3100 if creams are suggested as part of your treatment
The gut flora is considered to be a large secretory organ, which produces trimethylamine-N-oxide (TMAO), short-chain fatty acids and secondary bile acids by breaking down the ingested food
"Additionally, GLP-1 agonists can cause gastrointestinal side effects like nausea, vomiting, and diarrhoea
Myokine alterations, insulin resistance, dysregulation of protein metabolism, muscle oxidative stress, neuromuscular junction impairment, and increased ectopic intramuscular fat deposits may play roles in muscle dysfunction in patients with acromegaly
